RE:RE:RE:One detail that I just noticedLast year management announced that BTD would be applied for by the end of 2022. We're 5 months into 2023 and they are still working on the submission.
I think it is very likely that second thoughts about the timing of the submission were based on communication with the FDA, the PI and the MSAB, along with the actual results that came in from the clinical trial sites. If, as Longholder99 writes, management decided to optimize our chances of achieving BTD and possibly AA by delaying the submission there is another way they can't win.
If they are more cautious about the claims they make in news releases they will be accused of being uncommunicative and will be advised by zealous posters to go out and hire a PR firm. If they go ahead and try to let shareholders know as much as they can they run the risk of being forced to backtrack on their projections for the good of the company and the good of shareholders themselves. And then they will be blamed for not living up to their promises!
Longholder99 wrote: Management can't win. If they are meticulous and use consultation to ensure our chances at BTD and possibly AA....it's taking too long. If they rushed and screwed up to please the children the masses would be running back to the OSC with another complaint. Watch and learn or sell your shares. Jeeze